Steven B. Rossi, CEO of Digital First Media, and Timothy A. Barton, former CEO of Freightquote.com, which he founded in 1998, to its board of directors, effective immediately.
According to a Brandperx survey, as many as 28% of doctors identified cost as the leading benefit when a new OTC is brought to market.
“Only 8% of leaders are good at both strategy and execution, which means you must discover the sweet spot of knowing yourself, your competitors and your terrain. The very best win with ‘ideas’ and are obsessed with their front-line customer relationships.” That was one of the key messages conveyed by Elevation Forum founder and Mack Elevation leader Dan Mack at the most recent Elevation Form held in Scottsdale, Ariz., on Friday.
Renflexis, marketed by Merck and developed by South Korea's Samsung Bioepis, is the second FDA-approved biosimilar to Johnson & Johnson’s Remicade.
L’Oréal’s efforts have put sustainable product innovation front and center, pledging that all of its new or renovated products will have an improved social or environmental profile by 2020.
Casey Carl, who departs his position as chief innovation and strategy officer, effective May 5, joined the company in 1997, and has held various positions in merchandising, negotiations, operations and digital.
José (Joe) E. Almeida has more than 25 years of experience in health care, including medical devices, consumer health products, surgical instruments and biopharmaceuticals.
Perphenazine Tablets USP, 2 mg, 4 mg, 8 mg and 16 mg are the generic version of the reference listed drug, Trilafon Tablets 2 mg, 4 mg, 8 mg and 16 mg, originally marketed by Schering.
National Association of Chain Drug Stores president and CEO Steve Anderson writes about how the organization’s engaged membership constantly fuel's reinvention in how NACDS navigates business, politics and policy.